Acadian Asset Management LLC Acquires 379,677 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Acadian Asset Management LLC lifted its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 180.9% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 589,585 shares of the company’s stock after purchasing an additional 379,677 shares during the quarter. Acadian Asset Management LLC owned 0.05% of Teva Pharmaceutical Industries worth $8,315,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Blue Trust Inc. boosted its holdings in Teva Pharmaceutical Industries by 92.3% in the 4th quarter. Blue Trust Inc. now owns 4,541 shares of the company’s stock valued at $46,000 after purchasing an additional 2,180 shares during the period. Psagot Value Holdings Ltd. Israel bought a new stake in Teva Pharmaceutical Industries during the fourth quarter valued at $57,000. Newbridge Financial Services Group Inc. purchased a new position in Teva Pharmaceutical Industries during the fourth quarter worth about $82,000. Desjardins Global Asset Management Inc. increased its stake in Teva Pharmaceutical Industries by 15.2% in the 4th quarter. Desjardins Global Asset Management Inc. now owns 8,123 shares of the company’s stock worth $85,000 after acquiring an additional 1,070 shares during the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S purchased a new stake in shares of Teva Pharmaceutical Industries in the 1st quarter valued at about $93,000. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Price Performance

Shares of Teva Pharmaceutical Industries stock traded up $0.22 during trading on Monday, hitting $17.03. The company’s stock had a trading volume of 4,209,945 shares, compared to its average volume of 10,299,653. Teva Pharmaceutical Industries Limited has a 52 week low of $8.06 and a 52 week high of $17.69. The company has a fifty day simple moving average of $16.74 and a two-hundred day simple moving average of $14.36. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.20.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, May 8th. The company reported $0.46 earnings per share for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.03). Teva Pharmaceutical Industries had a negative net margin of 2.88% and a positive return on equity of 37.33%. The business had revenue of $3.82 billion for the quarter, compared to the consensus estimate of $3.70 billion. On average, equities research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.32 EPS for the current fiscal year.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Vikki L. Conway sold 15,219 shares of the business’s stock in a transaction on Monday, May 13th. The stock was sold at an average price of $16.74, for a total value of $254,766.06. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Teva Pharmaceutical Industries news, insider Vikki L. Conway sold 15,219 shares of the firm’s stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $16.74, for a total transaction of $254,766.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Roberto Mignone sold 519,000 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, June 18th. The stock was sold at an average price of $17.03, for a total transaction of $8,838,570.00. Following the completion of the transaction, the director now directly owns 981,000 shares of the company’s stock, valued at $16,706,430. The disclosure for this sale can be found here. Insiders sold a total of 549,719 shares of company stock valued at $9,353,736 in the last 90 days. Corporate insiders own 0.55% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently commented on TEVA shares. Piper Sandler reissued an “overweight” rating and set a $20.00 price objective (up previously from $19.00) on shares of Teva Pharmaceutical Industries in a report on Monday, May 13th. Jefferies Financial Group boosted their price target on shares of Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, June 27th. StockNews.com cut Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Monday, May 20th. Bank of America increased their price objective on Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the company a “buy” rating in a research note on Thursday, May 30th. Finally, Barclays increased their price target on shares of Teva Pharmaceutical Industries from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 5th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, Teva Pharmaceutical Industries presently has a consensus rating of “Moderate Buy” and an average target price of $18.56.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.